Objective: To determine the relationship between serum uric acid level and non-motor symptoms using the PD specific non-motor symptoms in Nigerian patients with Parkinson’s disease.

Background: Uric acid in low levels have been associated with rapid progression of motor symptoms of Parkinson disease, increased disease severity and increased frequency of non-motor symptoms. There is a paucity of studies on serum uric acid and non-motor symptoms in Parkinson’s disease. This study was conceptualized to determine the relationship between serum uric acid levels and the frequency of non-motor symptoms especially in Parkinson’s disease patient of African descent.

Methods: This was a 6-month analytical cross-sectional study recruiting 70 patients with Parkinson’s disease and 140 age and gender matched controls. Parkinson’s disease patients who met the inclusion criteria for the study were recruited consecutively from the Movement Disorders Clinic of the Lagos University Teaching Hospital. Healthy controls who met the inclusion criteria for controls were also recruited from volunteers. The non-motor symptoms were assessed with the Non-Motor Questionnaire. Serum uric acid measurement was determined on 5 mls of non-fasting venous blood drawn from each participant from a peripheral vein.

Results: Mean serum uric acid in PD (2.43 ± 0.75 mg/dl) was significantly lower than in controls (3.73 ± 1.09 mg/dl) (p <0.001). The non-motor symptoms that showed an independent correlation with serum uric acid using multivariate logistic regression analysis were loss of taste/smell with odds ratio of 0.411 (95% confidence interval (CI) of 0.196 – 0.863) and memory impairment with odd ratio of 0.466 (95% confidence interval of 0.229 – 0.948).

Conclusions: Low serum uric acid showed that serum uric acid is low in patients with Parkinson’s disease and associated with increased frequency of non-motor symptoms. It could predict the occurrence of memory impairment and loss of taste/smell.

References: 1. Foltynie T, Brayne CEG, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127(3):550–60. 2. Kirkwood TBL. The most pressing problem of our age. BMJ Br Med J. 2003;326:1297–9. 3. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601. 4. Diem-Zangerl A, Seppi K, Wenning GK, Trinka E, Ransmayr G, Oberaigner W, et al. Mortality in Parkinson’s disease: A 20-year follow-up study. Mov Disord. 2009;24(6):819–25. 5. Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson’s disease: Advances and strategies. Park Relat Disord [Internet]. 2016;22:S106–10. Available from: http://dx.doi.org/10.1016/j.parkreldis.2015.09.048. 5. De Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol. 2005;58(5):797–800. 6. Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007;166(5):561–7. 7. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM. Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol [Internet]. 1996;144(5):480–4. 8. Chen H, Mosley TH, Alonso A, Huang X. Plasma urate and Parkinson’s disease in the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol [Internet]. 2009;169(9):1064–9. 9. Elin RJ, Johnson E, Chesler R. Four methods for determining uric acid compared with a candidate reference method. Clin Chem. 1982;28(10):2098–100. 10. Trisnadewi K, Pangkahila WI, Purwata TE, Widyadharma IPE. Low Serum Uric Acid Level Increased the Risk of Parkinson’s Disease Low Serum Uric Acid Level Increased the Risk of Parkinson’s Disease. Int J Sci Res. 2017;6(April):2–7. 11. Bugalho P, Lampreia T, Miguel R, Mendonça MD, Caetano A, Barbosa R. Non-Motor symptoms in Portuguese Parkinson’s Disease patients: Correlation and impact on Quality of Life and Activities of Daily Living. Sci Rep [Internet]. 2016;6(March):1–9. 12. Park H, Lee JY, Shin CM, Kim JWJ-M, Kim TJ, Kim JWJ-M. Characterization of gastrointestinal disorders in patients with parkinsonian syndromes. Parkinsonism Relat Disord [Internet]. 2015;21(5):455–60. 13. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease: a comprehensive symptom survey. Park Relat Disord [Internet]. 2002;8(4):277–84. 14. Kaye J, Gage H, Kimber A, Storey L, Trend P. Excess burden of constipation in Parkinson’s disease: A pilot study. Mov Disord. 2006;21(8):1270–3. 15. Ueki A, Otsuka M. Life style risks of Parkinson’s disease: Association between decreased water intake and constipation. In: Journal of Neurology. 2004. 16. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: A dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33(6):599–614. 17. Okunoye OC. Non-Motor Features in Parkinson’s Disease Patients Attending Neurology Clinic at a Tertiary Institution in Nigeria: A Preliminary Report. AJOL. 2014;14(N0 3):114. 18. Smith M, Seth J, Batla A, Hofereiter J, Bhatia KP, Panicker JN. Nocturia in Patients With Parkinson’s Disease. Mov Disord Clin Pract [Internet]. 2016;3(2):168–72. 19. Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, et al. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson’s disease. Eur J Neurol. 2015;22(1):93–8.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/serum-uric-acid-level-and-its-relationship-to-non-motor-symptomatology-in-parkinsons-disease/